Apollo Hospitals Q1 FY26 PAT up 42% to Rs. 433 Cr
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
AINU is set to accelerate its expansion footprint, enhance operational capabilities
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Subscribe To Our Newsletter & Stay Updated